Kaixing Life Technology (Shanghai) Co Ltd registered in the bonded area, a wholly-owned subsidiary of CARsgen Therapeutics, recently received approval from the National Medical Products Administration to market its CAR-T product, zervor-cel injection, which is mainly used to treat relapsed or refractory multiple myeloma in adult patients.
This is the first CAR-T product approved for marketing from the bonded area and the first independently developed CAR-T product in Shanghai. It is also the fifth CAR-T product approved for marketing nationwide.
Established in 2018, Kaixing is an innovative enterprise in the field of biomedicine, mainly engaged in services such as technical services, technical development, technical consulting, technical exchange, technology transfer and technology promotion.
The biopharmaceutical industry is a strategic emerging industry and one of the key industries during the 14th Five-Year Plan period in the bonded area. The Waigaoqiao Biopharmaceutical Industrial Park has also been included in Shanghai's "1+5+X" biopharmaceutical industry layout.
In 2023, the biopharmaceutical industry in the bonded area achieved operating income of 306 billion yuan (US$42.56 billion), a 7.3 percent increase over the previous year, accounting for about one-third of Shanghai's total.
